BiotechTube

NX-1207

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS

Trial Timeline

Apr 1, 2013 → Oct 1, 2014

NCT ID
NCT01846793

About NX-1207

NX-1207 is a phase 3 stage product being developed by Nymox Pharmaceutical for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01846793. Target conditions include Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS).

What happened to similar drugs?

10 of 20 similar drugs in Benign Prostatic Hyperplasia were approved

Approved (10) Terminated (1) Active (9)
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
✅Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved
✅Tamsulosin OCAS + PlaceboAstellas PharmaApproved
✅Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
✅ErtapenemMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01846793Phase 3Completed
NCT01438775Phase 3Completed

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
43
ASP4901 + Tamsulosin + PlaceboAstellas PharmaPhase 2
35
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Tamsulosin OCASAstellas PharmaApproved
43
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
39
Tadalafil + PlaceboEli LillyPhase 2
35
TadalafilEli LillyPhase 1
29
Tadalafil + Placebo + TamsulosinEli LillyPhase 3
40
Tadalafil 2.5 mg + Tadalafil 5 mg + PlaceboEli LillyPhase 2
35
Tadalafil 5 mg + Placebo tablet + Tamsulosin + Placebo capsuleEli LillyPhase 3
40
Tadalafil + PlaceboEli LillyPhase 3
40
Tadalafil + Placebo + TamsulosinEli LillyPhase 2
35
Tadalafil + PlaceboEli LillyPhase 3
40
tadalafil + tadalafil + tadalafil + tadalafil + placeboEli LillyPhase 2/3
38